Results 1 to 10 of about 5,596 (124)

Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity [PDF]

Endocrinology, Diabetes & Metabolism Case Reports
We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide.
Hiroki Takizawa, Akiko Tsuda, Hidehisa Suriki, Hideki Amagane   +3 more
doaj   +2 more sources

Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis [PDF]

Endocrinology and Metabolism
Background Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra   +5 more
doaj   +1 more source

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Cardiovascular Diabetology, 2023
Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes.
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, Xuewei Cui, Ciara O’Neill, Laura Fernández Landó, Hiren Patel   +6 more
doaj   +1 more source

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review

Biomedicines, 2023
The prevalence of metabolic diseases including type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for identifying optimal therapies for the management of these conditions ...
Alexandros Leonidas Liarakos, Chrysi Koliaki   +1 more
doaj   +1 more source

Tirzepatide for type 2 diabetes

Drugs in Context, 2023
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI Insight, 2020
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.
Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop   +17 more
doaj   +1 more source

Tirzepatide (Mounjaro)-induced acute pancreatitis and ketoacidosis in an adult nondiabetic patient

Saudi Journal for Health Sciences
Tirzepatide (Mounjaro) is a new medication approved for type 2 diabetes and obesity treatment. It works by activating the receptors for both glucose-dependent insulinotropic peptide and glucagon-like peptide-1.
Asma Ali Sallam, Bdoor Attaulla Alenezi, Muneerah M. Albugami   +2 more
doaj   +1 more source

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue

Molecular Metabolism, 2022
Objectives: Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D).
Ricardo J. Samms, GuoFang Zhang, Wentao He, Olga Ilkayeva, Brian A. Droz, Steven M. Bauer, Cynthia Stutsman, Valentina Pirro, Kyla A. Collins, Ellen C. Furber, Tamer Coskun, Kyle W. Sloop, Joseph T. Brozinick, Christopher B. Newgard   +13 more
doaj   +1 more source

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review

Journal of Education, Health and Sport, 2023
Background: Obesity is a chronic disease, which along with its complications, poses a huge threat to both our health as individuals and our healthcare as a community.
Bartłomiej Stachyra, Marta Wolanin, Cezary Stawikowski, Bartłomiej Zielonka, Aleksandra Osińska, Izabela Wolanin, Karolina Madej, Barbara Dengler, Ilona Kowalczyk, Paulina Krawiec   +9 more
doaj   +1 more source

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist

Journal of Lipid and Atherosclerosis, 2023
Glucagon-like peptide-1 (GLP-1) receptor agonists have been used extensively in the clinic and have an established safety profile in cardiovascular disease settings.
Yun Kyung Cho, Yoo La Lee, Chang Hee Jung   +2 more
doaj   +1 more source